| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Blonder Tongue Laboratories, Inc. (NYSE American:BDR) today announced its delisting from the NYSE American and commencement of trading on the OTCQB.
As previously disclosed, Blonder Tongue Laboratories, Inc. (the "Company") received written notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation had determined to commence proceedings to delist the common stock of the Company (the "Common Stock") from the Exchange. NYSE Regulation staff has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the "Company Guide") as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on December 10, 2021.
The Company appealed such determination, and a hearing was scheduled to take place on June 28, 2022. On June 24, 2022, after the Company's Board of Directors determined the Company will not be able to regain compliance with the above referenced listing standards in the short term, the Company canceled the appeal hearing and requested its Common Stock be withdrawn from being listed on the Exchange. As a result, we expect the trading of the Common Stock on the Exchange to be terminated on June 24, 2022.
The Company expects the Common Stock to commence trading under the symbol "BDRL" on the OTCQB marketplace operated by OTC Markets Group Inc. The Company expects the Common Stock to commence trading on the OTCQB on June 27, 2022.
Posted In: BDR
